Scarica l'app Stockscreener
35.57
1.93%
-0.70
Dopo l'orario di chiusura:
36.05
0.48
+1.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$36.27
Aprire:
$35.47
Volume 24 ore:
1.93M
Relative Volume:
0.60
Capitalizzazione di mercato:
$5.46B
Reddito:
-
Utile/perdita netta:
$-284.08M
Rapporto P/E:
-14.68
EPS:
-2.4234
Flusso di cassa netto:
$-234.65M
1 W Prestazione:
+0.14%
1M Prestazione:
-11.74%
6M Prestazione:
+263.70%
1 anno Prestazione:
+338.59%
Intervallo 1D:
$34.61
$36.05
Intervallo di 1 settimana:
$32.93
$37.00
Portata 52W:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Confronta COGT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
35.57 | 5.57B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Will Cogent Biosciences Inc. stock split again soon2025 Volume Leaders & Reliable Price Breakout Signals - ulpravda.ru
Why Cogent Biosciences Inc. stock is in analyst buy zone2025 EndofYear Setup & Free Technical Confirmation Trade Alerts - ulpravda.ru
Is Cogent Biosciences Inc. stock a buy for dividend growth2025 Trading Volume Trends & Fast Gain Swing Alerts - ulpravda.ru
How Cogent Biosciences Inc. stock performs during Fed tightening cyclesMarket Movers & Safe Entry Point Identification - ulpravda.ru
Will Cogent Biosciences Inc. stock deliver long term returnsWeekly Risk Summary & Low Volatility Stock Suggestions - ulpravda.ru
Will Cogent Biosciences Inc. stock attract more institutional investorsJuly 2025 Sentiment & Verified Entry Point Detection - ulpravda.ru
Does Cogent Biosciences Inc. stock trade at a discount to peersJuly 2025 Market Mood & Smart Swing Trading Alerts - ulpravda.ru
Cogent Biosciences announces presentation at the 44th annual J.P. Morgan Healthcare conference - MarketScreener
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COG - GuruFocus
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COGT Stock News - GuruFocus
Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily
Cogent Biosciences down after market close on insider sales - MSN
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Best Biotech Stocks To Follow TodayDecember 31st - MarketBeat
Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding - simplywall.st
EV Market: Will Cogent Biosciences Inc stock see PE expansionJuly 2025 News Drivers & Capital Efficiency Focused Ideas - moha.gov.vn
Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. - Barron's
Cogent Biosciences Stock Jumps in 2025 as Executives Sell Shares - Barron's
Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside as Analysts Show Strong Buy Interest - DirectorsTalk Interviews
When Will Cogent Biosciences, Inc. (NASDAQ:COGT) Become Profitable? - 富途牛牛
Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing - ts2.tech
Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling - MarketBeat
Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News - Trefis
Wave of High-Level Insider Sales Rocks Cogent Biosciences - TipRanks
Cogent Biosciences presents full SUMMIT results of bezuclastinib - MSN
Insider Sell: Jessica Sachs Sells 82,642 Shares of Cogent Biosci - GuruFocus
Cogent Biosciences (COGT) Shares Drop Following Insider Sales - GuruFocus
Cogent Biosciences stock falls after multiple insider sales By Investing.com - Investing.com UK
Cogent Biosciences stock falls after multiple insider sales - Investing.com
Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares - MarketBeat
Cogent Biosciences Insider Sold Shares Worth $3,486,600, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $3,198,245, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $2,978,360, According to a Recent SEC Filing - MarketScreener
Cogent Biosciences Insider Sold Shares Worth $2,515,500, According to a Recent SEC Filing - MarketScreener
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis - The Globe and Mail
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib - ts2.tech
Cogent Biosciences Submits New Drug Application for Bezuclastinib for Non-Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences (COGT) Advances Bezuclastinib with FDA Submis - GuruFocus
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
New drug for systemic mastocytosis moves into FDA review - Stock Titan
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update - Insider Monkey
Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis - MSN
Certain Stock Options of Cogent Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2025. - MarketScreener
Price-Driven Insight from (COGT) for Rule-Based Strategy - Stock Traders Daily
Squarepoint Ops LLC Purchases Shares of 101,518 Cogent Biosciences, Inc. $COGT - MarketBeat
What analysts say about Cogent Biosciences Inc stockMarket Sentiment Surveys & Avoid Market Traps With Pro-Level Warnings - earlytimes.in
Cogent Biosciences Earnings Notes - Trefis
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):